Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5968352 | 0.79 | GRM4 (0.32) | CYP3A4MAPK1GRM4LMNAMAPT | |
| SCHEMBL378661 | 0.79 | FGFR1 (0.30) | — | |
| SCHEMBL5613530 | 0.78 | IDO1 (0.38) | IDO1MAPT | |
| SCHEMBL1154416 | 0.76 | — | — | |
| SCHEMBL21313860 | 0.76 | HTR2A (0.31) | — | |
| SCHEMBL1020657 | 0.76 | GRM4 (0.33) | GRM4 | |
| SCHEMBL6267453 | 0.76 | HPGD (0.37) | CYP3A4HSP90AA1TSHR | |
| SCHEMBL8622721 | 0.76 | ADRB2 (0.33) | KDM4E | |
| SCHEMBL2995564 | 0.76 | DPP4 (0.36) | CYP3A4GRM4KDM4EBRD4LMNA | |
| SCHEMBL9172776 | 0.74 | DPP4 (0.35) | CYP3A4GRM4KDM4EBRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150112084-A1 | PROCESS FOR PREPARATION OF (IS, 3S, 5S)-2-[(2S)-2-AMIN0-2-(3-HYDROXY-l-ADAMANTYL) ACETYL]-2-AZABICYCLO [3.1.0] HEXANE-3-CARBONITRILE | DAVULURI, RAMAMOHAN RAO (IN) | 2015-04-23 | — | — | US | claimed |
| EP-2855432-A1 | PROCESS FOR PREPARATION OF (1S, 3S, 5S)-2-[(2S)-2-AMINO-2-(3-HYDROXY-1-ADAMANTYL) ACETYL]-2-AZABICYCLO [3.1.0]HEXANE-3-CARBONITRILE | Davuluri, Ramamohan Rao (IN) | 2015-04-08 | — | — | EP | claimed |
| WO-2013179297-A1 | PROCESS FOR PREPARATION OF (1S, 3S, 5S)-2-[(2S)-2-AMINO-2-(3-HYDROXY-1-ADAMANTYL) ACETYL]-2-AZABICYCLO [3.1.0] HEXANE-3-CARBONITRILE | RAO DAVULURI RAMAMOHAN (IN) | 2013-12-05 | — | — | WO | claimed |
| EP-2655527-A1 | PROCESS FOR CURING SURFACE-COATING COMPOSITIONS | ALLNEX AUSTRIA GmbH (AT) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085016-A1 | PROCESS FOR CURING SURFACE-COATING COMPOSITIONS | CYTEC AUSTRIA GMBH (AT) | 2012-06-28 | — | — | WO | claimed |
| US-20090182057-A1 | DEUTERATED AMINOGLYCIDAL COMPOUNDS | AUSPEX PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182057-A1 | DEUTERATED AMINOGLYCIDAL COMPOUNDS | ADRB2, GLRB, ADRB1 | CYP3A4 1580/4885MAPK1 3793/4885GRM4 2776/4885 |
| US-20150112084-A1 | PROCESS FOR PREPARATION OF (IS, 3S, 5S)-2-[(2S)-2-AMIN0-2-(3-HYDROXY-l-ADAMANTYL) ACETYL]-2-AZABICYCLO [3.1.0] HEXANE-3-CARBONITRILE | DPP4, DPP3, DPP9 | CYP3A4 80/4885MAPK1 1324/4885GRM4 3350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.